Sugi Predict

Sugi Predict / Compounds / SCHEMBL20674147

SCHEMBL20674147

SCHEMBL20674147

CC(O)c1nc(O)n2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.39
▸ KMT2A Q03164 4/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ PTPN2 P17706 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ TSHR P16473 3/20 0.35
▸ MIF P14174 2/20 0.35
▸ PDE5A O76074 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ PDE4A P27815 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20674504 0.74 PTPN1 (0.56) KMT2AMEN1PTPN2PTPN1ALDH1A1
SCHEMBL20673907 0.73 USP7 (0.51) TDP1KMT2AMEN1ALDH1A1USP7
SCHEMBL20674622 0.72 TDP1 (0.46) TDP1KMT2AMEN1PTPN2PTPN1
SCHEMBL20673884 0.70 USP7 (0.48) KMT2AMEN1PTPN2PTPN1ALDH1A1
SCHEMBL20674150 0.69 BAZ2B (0.46) KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E
SCHEMBL20674152 0.69 SSTR4 (0.37) KMT2AMEN1PTPN2PTPN1ALDH1A1
SCHEMBL20674156 0.68 HIF1A (0.43) KMT2AMEN1PTPN2PTPN1ALDH1A1
SCHEMBL18878436 0.68 HTR4 (0.44) KMT2AMEN1PTPN2PTPN1ALDH1A1
SCHEMBL21180241 0.68 HTR4 (0.43) KMT2AMEN1ALDH1A1TSHRMIF
SCHEMBL20674505 0.67 ALDH1A1 (0.56) KMT2AMEN1ALDH1A1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE CS PHARMATECH LIMITED (KY) 2020-04-30 — — US disclosed
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase CS PHARMATECH LIMITED (KY) 2019-10-08 — — US disclosed
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE HIGH GREAT INVESTMENT LIMITED (HK) 2019-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10435388-B2 Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase EGFR, ERBB3, ERBB2 TDP1 2687/4885KMT2A 2411/4885MEN1 3422/4885
US-20200131176-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 TDP1 2436/4885KMT2A 2302/4885MEN1 3396/4885
US-20190023689-A1 SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE EGFR, ERBB3, ERBB2 TDP1 2687/4885KMT2A 2411/4885MEN1 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.